-
公开(公告)号：US20070280899A1
公开(公告)日：2007-12-06
申请号：US11748723
申请日：2007-05-15
IPC分类号： A61K31/765
CPC分类号： C12P7/625 , A61B17/06166 , A61B42/00 , A61K47/593 , A61K47/6957 , A61L15/26 , A61L17/10 , A61L27/18 , A61L27/34 , A61L29/06 , A61L31/06 , C08G63/06 , C08G63/6852 , C08G63/6882 , C08G63/912 , C12N5/0068 , C12N2533/30 , Y10S977/775 , Y10T428/139 , C08L67/04
摘要： Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses. Properties which are selected for include degradability, elasticity, inclusion of functional groups or derivatized groups, which can in turn be used to attach targeting agents, and bioadhesion.
摘要翻译： 已经除去热原的聚羟基链烷酸酯（PHA）被提供用于许多生物医学应用。 已经化学改性以增强物理和/或化学性质的PHA用于通过网状内皮系统（RES）靶向或修饰生物降解性或清除的PHA。 还提供了通过细菌发酵方法制备的去氢原位PHA聚合物的方法，其中热原从聚合物中除去而不会不利地影响聚合物固有的化学结构和物理性质。 还描述了具有有利处理特性的PHA，包括低熔点和/或在无毒溶剂中的溶解度。 提供适用于体内应用的PHA，例如在组织包衣，支架，缝线，管，骨和其他假体，骨或组织水泥，组织再生装置，伤口敷料，药物递送以及诊断和预防用途中。 选择的性质包括降解性，弹性，包含官能团或衍生基团，其又可用于附着靶向剂，以及生物粘附。
-
2.发明授权Method for making devices using polyhydroxyalkanoate having pyrogen removed 有权使用除去热原原子的聚羟基链烷酸酯制造器件的方法公开(公告)号：US07244442B2
公开(公告)日：2007-07-17
申请号：US10642026
申请日：2003-08-15
CPC分类号： C12P7/625 , A61B17/06166 , A61B42/00 , A61K47/593 , A61K47/6957 , A61L15/26 , A61L17/10 , A61L27/18 , A61L27/34 , A61L29/06 , A61L31/06 , C08G63/06 , C08G63/6852 , C08G63/6882 , C08G63/912 , C12N5/0068 , C12N2533/30 , Y10S977/775 , Y10T428/139 , C08L67/04
摘要： Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses. Properties which are selected for include degradability, elasticity, inclusion of functional groups or derivatized groups, which can in turn be used to attach targeting agents, and bioadhesion.
摘要翻译： 已经除去热原的聚羟基链烷酸酯（PHA）被提供用于许多生物医学应用。 已经化学改性以增强物理和/或化学性质的PHA用于通过网状内皮系统（RES）靶向或修饰生物降解性或清除的PHA。 还提供了通过细菌发酵方法制备的PHA聚合物去热原化方法，其中热原从聚合物中除去而不会不利地影响聚合物固有的化学结构和物理性质。 还描述了具有有利处理特性的PHA，包括低熔点和/或在无毒溶剂中的溶解度。 提供适用于体内应用的PHA，例如在组织涂层，支架，缝线，管，骨和其他假体，骨或组织水泥，组织再生装置，伤口敷料，药物递送以及用于诊断和预防用途 。 选择的性质包括降解性，弹性，包含官能团或衍生基团，其又可用于附着靶向剂，以及生物粘附。
-
公开(公告)号：US20060148035A1
公开(公告)日：2006-07-06
申请号：US11271235
申请日：2005-11-10
申请人： Tillman Gerngross
发明人： Tillman Gerngross
CPC分类号： C12P21/005 , C07K2319/04 , C07K2319/05 , C12N1/14 , C12N9/1048 , C12N9/2488 , C12N15/79 , C12N15/80 , C12N15/81 , C12Y302/01 , C12Y302/01113
摘要： Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways. This is achieved using a combination of engineering and/or selection of strains which: do not express certain enzymes which create the undesirable complex structures characteristic of the fungal glycoproteins, which express exogenous enzymes selected either to have optimal activity under the conditions present in the fungi where activity is desired, or which are targeted to an organelle where optimal activity is achieved, and combinations thereof wherein the genetically engineered eukaryote expresses multiple exogenous enzymes required to produce “human-like” glycoproteins.
摘要翻译： 已经开发了具有遗传修饰的糖基化途径的细胞系，其允许它们进行模拟人类中糖蛋白的加工的酶反应序列。 在这些工程化宿主中表达的重组蛋白可以产生与其对应物更相似的糖蛋白（如果基本上不相同）。 通常产生含有高甘露糖的N-聚糖（包括单细胞和多细胞真菌）的低等真核生物被修饰以产生N-聚糖，例如Man 3或GlcNAc 2 N或其它结构 沿着人类糖基化途径。 这是使用以下工程和/或选择的组合实现的：不表达产生真菌糖蛋白特征的不合需要的复合结构的某些酶，其表达选择在真菌中存在的条件下具有最佳活性的外源酶 其中需要活性或靶向实现最佳活性的细胞器，以及其组合，其中遗传工程真核生物表达产生“人样”糖蛋白所需的多种外源酶。
-
4.发明申请Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform 审中-公开主要包含GlcNAcMAN5GLCNAC2糖型的免疫球蛋白公开(公告)号：US20060034828A1
公开(公告)日：2006-02-16
申请号：US11187066
申请日：2005-07-21
申请人： Tillman Gerngross , Huijuan Li , Stefan Wildt
发明人： Tillman Gerngross , Huijuan Li , Stefan Wildt
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06
CPC分类号： C07K16/00 , C07K16/2896 , C07K2317/24 , C07K2317/41 , C07K2317/732
摘要： The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is GlcNAcMan5GlcNAc2.
摘要翻译： 本发明涉及在赋予特异性效应子功能的免疫球蛋白糖蛋白上具有主要N-聚糖结构的免疫球蛋白糖蛋白组合物。 另外，本发明涉及包含具有特定富集的N-聚糖结构的抗体的药物组合物，其中所述N-聚糖结构是GlcNAcMan 5 GlcNAc 2。
-
5.发明授权公开(公告)号：US07906135B2
公开(公告)日：2011-03-15
申请号：US11748723
申请日：2007-05-15
CPC分类号： C12P7/625 , A61B17/06166 , A61B42/00 , A61K47/593 , A61K47/6957 , A61L15/26 , A61L17/10 , A61L27/18 , A61L27/34 , A61L29/06 , A61L31/06 , C08G63/06 , C08G63/6852 , C08G63/6882 , C08G63/912 , C12N5/0068 , C12N2533/30 , Y10S977/775 , Y10T428/139 , C08L67/04
摘要： Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses. Properties which are selected for include degradability, elasticity, inclusion of functional groups or derivatized groups, which can in turn be used to attach targeting agents, and bioadhesion.
摘要翻译： 已经除去热原的聚羟基链烷酸酯（PHA）被提供用于许多生物医学应用。 已经化学改性以增强物理和/或化学性质的PHA用于通过网状内皮系统（RES）靶向或修饰生物降解性或清除的PHA。 还提供了通过细菌发酵方法制备的去氢原位PHA聚合物的方法，其中热原从聚合物中除去而不会不利地影响聚合物固有的化学结构和物理性质。 还描述了具有有利处理特性的PHA，包括低熔点和/或在无毒溶剂中的溶解度。 提供适用于体内应用的PHA，例如在组织包衣，支架，缝线，管，骨和其他假体，骨或组织水泥，组织再生装置，伤口敷料，药物递送以及诊断和预防用途中。 选择的性质包括降解性，弹性，包含官能团或衍生基团，其又可用于附着靶向剂，以及生物粘附。
-
公开(公告)号：US20070178551A1
公开(公告)日：2007-08-02
申请号：US11265444
申请日：2005-11-01
申请人： Tillman Gerngross
发明人： Tillman Gerngross
CPC分类号： C12P21/005 , C07K2319/04 , C07K2319/05 , C12N1/14 , C12N9/1048 , C12N9/2488 , C12N15/79 , C12N15/80 , C12N15/81 , C12Y302/01 , C12Y302/01113
摘要： Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways. This is achieved using a combination of engineering and/or selection of strains which: do not express certain enzymes which create the undesirable complex structures characteristic of the fungal glycoproteins, which express exogenous enzymes selected either to have optimal activity under the conditions present in the fungi where activity is desired, or which are targeted to an organelle where optimal activity is achieved, and combinations thereof wherein the genetically engineered eukaryote expresses multiple exogenous enzymes required to produce “human-like” glycoproteins.
摘要翻译： 已经开发了具有遗传修饰的糖基化途径的细胞系，其允许它们进行模拟人类中糖蛋白的加工的酶反应序列。 在这些工程化宿主中表达的重组蛋白可以产生与其对应物更相似的糖蛋白（如果基本上不相同）。 通常产生含有高甘露糖的N-聚糖（包括单细胞和多细胞真菌）的低等真核生物被修饰以产生N-聚糖，例如Man 3或GlcNAc 2 N或其它结构 沿着人类糖基化途径。 这是使用以下工程和/或选择的组合实现的：不表达产生真菌糖蛋白特征的不合需要的复合结构的某些酶，其表达选择在真菌中存在的条件下具有最佳活性的外源酶 其中需要活性或靶向实现最佳活性的细胞器，以及其组合，其中遗传工程真核生物表达产生“人样”糖蛋白所需的多种外源酶。
-
公开(公告)号：US20060040353A1
公开(公告)日：2006-02-23
申请号：US11108088
申请日：2005-04-15
申请人： Robert Davidson , Tillman Gerngross , Stefan Wildt , Byung-Kwon Choi , Juergen Nett , Piotr Bobrowicz , Stephen Hamilton
发明人： Robert Davidson , Tillman Gerngross , Stefan Wildt , Byung-Kwon Choi , Juergen Nett , Piotr Bobrowicz , Stephen Hamilton
CPC分类号： C12P21/005 , C12N9/1051 , C12N15/1082 , C12N15/79 , Y10S435/911
摘要： The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal β-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein.
摘要翻译： 本发明提供了一种产生人样糖蛋白的新型低级真核宿主细胞，其特征在于具有末端β-半乳糖残基并且基本上缺乏岩藻糖和唾液酸残基。 本发明还提供了一种催化将半乳糖残基从UDP-半乳糖转移到可用作治疗性糖蛋白的重组低等真核宿主细胞中的受体底物上的方法。
-
8.发明授权Medical device containing polyhydroxyalkanoate treated with oxidizing agent to remove endotoxin 有权包含用氧化剂处理以除去内毒素的聚羟基链烷酸酯的医疗装置公开(公告)号：US06623749B2
公开(公告)日：2003-09-23
申请号：US09819447
申请日：2001-03-28
IPC分类号： A61F200
CPC分类号： C12P7/625 , A61B17/06166 , A61B42/00 , A61K47/593 , A61K47/6957 , A61L15/26 , A61L17/10 , A61L27/18 , A61L27/34 , A61L29/06 , A61L31/06 , C08G63/06 , C08G63/6852 , C08G63/6882 , C08G63/912 , C12N5/0068 , C12N2533/30 , Y10S977/775 , Y10T428/139 , C08L67/04
摘要： Polyhydroxyalkanoate (PHA) that contains a pyrogen such as an endotoxin due to a process of producing the PHA is treated to remove the pyrogen by a process that does not affect the inherent chemical and physical properties of the PHA to obtain a biocompatible PHA. PHA produced by fermentation with a Gram negative bacteria can be treated with an oxidizing agent such as hydrogen peroxide or benzoyl peroxide to reduce the endotoxin content to less than 20 endotoxin units/gram of PHA to produce PHA that does not elicit an acute inflammatory response when implanted in an animal. The PHA may have a melting point or glass transition temperature less than 136° C., and can be chemically modified or derivatized such as by covalently coupling an attachment or targeting molecule. The PHA may be used to form various medical devices, and can be used for in vivo applications including tissue coatings, stents, sutures, tubing, bone and other prostheses, bone and tissue cements, issue regenerating devices, wound dressings, drug delivery, and diagnostic and prophylactic uses.
摘要翻译： 通过不影响PHA的固有化学和物理性能以获得生物相容性PHA的方法，处理含有由热生物引起的热源（例如内毒素）的聚羟基链烷酸酯（PHA），由此产生PHA。 通过用革兰氏阴性细菌发酵产生的PHA可以用氧化剂如过氧化氢或过氧化苯甲酰处理以将内毒素含量降低到小于20个内毒素单位/克的PHA，以产生不引起急性炎症反应的PHA 植入动物。 PHA可以具有低于136℃的熔点或玻璃化转变温度，并且可以通过共价偶联附着物或靶向分子进行化学修饰或衍生化。 PHA可以用于形成各种医疗装置，并且可以用于体内应用，包括组织涂层，支架，缝线，管，骨和其他假体，骨和组织水泥，发行再生装置，伤口敷料，药物递送和 诊断和预防用途。
-
公开(公告)号：US20110135707A1
公开(公告)日：2011-06-09
申请号：US13021419
申请日：2011-02-04
IPC分类号： A61F2/28 , C12N5/07 , A61F2/00 , A61K9/00 , A61K49/00 , A61K38/02 , A61K31/7088 , A61K31/715 , A61K31/70 , A61K31/20 , A61K9/70 , A61P17/02 , A61P19/08 , A61P9/00 , C08G63/91 , B32B1/08
CPC分类号： C12P7/625 , A61B17/06166 , A61B42/00 , A61K47/593 , A61K47/6957 , A61L15/26 , A61L17/10 , A61L27/18 , A61L27/34 , A61L29/06 , A61L31/06 , C08G63/06 , C08G63/6852 , C08G63/6882 , C08G63/912 , C12N5/0068 , C12N2533/30 , Y10S977/775 , Y10T428/139 , C08L67/04
摘要： Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers' inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses. Properties which are selected for include degradability, elasticity, inclusion of functional groups or derivatized groups, which can in turn be used to attach targeting agents, and bioadhesion.
摘要翻译： 已经除去热原的聚羟基链烷酸酯（PHA）被提供用于许多生物医学应用。 已经化学改性以增强物理和/或化学性质的PHA用于通过网状内皮系统（RES）靶向或修饰生物降解性或清除的PHA。 还提供了通过细菌发酵方法制备的PHA聚合物去热原化方法，其中热原从聚合物中除去而不会不利地影响聚合物固有的化学结构和物理性质。 还描述了具有有利处理特性的PHA，包括低熔点和/或在无毒溶剂中的溶解度。 提供适用于体内应用的PHA，例如在组织涂层，支架，缝线，管，骨和其他假体，骨或组织水泥，组织再生装置，伤口敷料，药物递送以及用于诊断和预防用途 。 选择的性质包括降解性，弹性，包含官能团或衍生基团，其又可用于附着靶向剂，以及生物粘附。
-
10.发明申请Immunoglobulins Comprising Predominantly a Glcnacman3Glcnac2 Glycoform 审中-公开免疫球蛋白主要包含Glcnacman3Glcnac2 Glycoform公开(公告)号：US20090136525A1
公开(公告)日：2009-05-28
申请号：US11990722
申请日：2006-09-01
申请人： Tillman Gerngross , Stefan Wildt , Huijuan Li
发明人： Tillman Gerngross , Stefan Wildt , Huijuan Li
IPC分类号： A61K39/395 , C12N5/10 , C12P21/00 , A61P37/00
CPC分类号： C07K16/2887 , C07K2317/24 , C07K2317/41 , C07K2317/72
摘要： Compositions and methods for producing compositions comprising immunoglobulins or immunoglobulin fragments having an N-linked glycosylation pattern consisting predominantly of the GlCNAcMan3GlcNAc2 N-glycan structure are disclosed. The GlCNAcMan3GlcNAc2 N-glycan structure effects an increase in binding to the FcγRiπ receptors and a decrease in binding to the FcγRH receptors.
摘要翻译： 公开了用于生产组合物的组合物和方法，其包含主要由GlCNAcMan 3 GlcNAc 2 N-聚糖结构组成的具有N-连接的糖基化模式的免疫球蛋白或免疫球蛋白片段。 GlCNAcMan3GlcNAc2 N-聚糖结构影响与FcγRipi受体的结合增加，并降低与FcγR受体的结合。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.038 秒)